4,874 reports of this reaction
5.5% of all OLANZAPINE PAMOATE reports
#1 most reported adverse reaction
DIABETES MELLITUS is the #1 most commonly reported adverse reaction for OLANZAPINE PAMOATE, manufactured by H2-Pharma LLC. There are 4,874 FDA adverse event reports linking OLANZAPINE PAMOATE to DIABETES MELLITUS. This represents approximately 5.5% of all 88,377 adverse event reports for this drug.
OLANZAPINE PAMOATE has an overall safety score of 85 out of 100. Patients taking OLANZAPINE PAMOATE who experience diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIABETES MELLITUS is moderately reported among OLANZAPINE PAMOATE users, representing a notable but not dominant share of adverse events.
In addition to diabetes mellitus, the following adverse reactions have been reported for OLANZAPINE PAMOATE:
The following drugs have also been linked to diabetes mellitus in FDA adverse event reports:
DIABETES MELLITUS has been reported as an adverse event in 4,874 FDA reports for OLANZAPINE PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIABETES MELLITUS accounts for approximately 5.5% of all adverse event reports for OLANZAPINE PAMOATE, making it one of the most commonly reported side effect.
If you experience diabetes mellitus while taking OLANZAPINE PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.